Increasing evidence has revealed an association between the transcriptional expression levels of ALKBH5 in tumor cells and poor clinical outcomes in GBM patients, indicating ALKBH5 as a potential therapeutic target in GBM 14, 47, 48. Here, ALKBH5 is linked to glioblastoma.